BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 15464708)

  • 1. Adverse effects of thalidomide administration in patients with neoplastic diseases.
    Dimopoulos MA; Eleutherakis-Papaiakovou V
    Am J Med; 2004 Oct; 117(7):508-15. PubMed ID: 15464708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palliative oncology: thalidomide.
    Prommer EE
    Am J Hosp Palliat Care; 2010 May; 27(3):198-204. PubMed ID: 19843880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomid: current role in the treatment of non-plasma cell malignancies.
    Kumar S; Witzig TE; Rajkumar SV
    J Clin Oncol; 2004 Jun; 22(12):2477-88. PubMed ID: 15197211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The revival of thalidomide: an old drug with new indications].
    Laffitte E
    Rev Prat; 2006 Nov; 56(18):1977-83. PubMed ID: 17274497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide for the treatment of multiple myeloma.
    Hattori Y; Iguchi T
    Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thalidomide. Clinical trials in cancer].
    Politi PM
    Medicina (B Aires); 2000; 60 Suppl 2():61-5. PubMed ID: 11188934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thalidomide: new uses for an old drug].
    Wu KL; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide: when everything old is new again.
    Nirenberg A
    Clin J Oncol Nurs; 2001; 5(1):15-8. PubMed ID: 11899395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.
    Witzens M; Moehler T; Neben K; Fruehauf S; Hartschuh W; Ho AD; Goldschmidt H
    Ann Hematol; 2004 Jul; 83(7):467-70. PubMed ID: 14625789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in oral therapy in the treatment of multiple myeloma.
    Doss DS
    Clin J Oncol Nurs; 2006 Aug; 10(4):514-20. PubMed ID: 16927905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Potential side effects of thalidomide].
    Rev Prat; 2006 Jan; 56(1):52. PubMed ID: 16548249
    [No Abstract]   [Full Text] [Related]  

  • 12. [Thalidomide in oncological and hematological diseases].
    Kivivuori SM; Anttila P
    Duodecim; 2010; 126(12):1413-9. PubMed ID: 20617746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
    Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
    Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.
    Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P
    Eur J Haematol; 2004 Jun; 72(6):403-9. PubMed ID: 15128418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dermatologic and nondermatologic uses of thalidomide.
    Nasca MR; Micali G; Cheigh NH; West LE; West DP
    Ann Pharmacother; 2003 Sep; 37(9):1307-20. PubMed ID: 12921515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide: present and future in multiple myeloma.
    Hussein MA
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
    Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
    J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thalidomide--new prospective therapy in oncology].
    Pałgan K; Pałgan I
    Wiad Lek; 2003; 56(9-10):455-9. PubMed ID: 15049211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma.
    Morabito A; Fanelli M; Carillio G; Gattuso D; Sarmiento R; Gasparini G
    Oncol Rep; 2004 Jan; 11(1):93-5. PubMed ID: 14654909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide: current therapeutic uses and management of its toxicities.
    Tariman JD
    Clin J Oncol Nurs; 2003; 7(2):143-7. PubMed ID: 12696209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.